Liang R, Chiu E, Chan T K, Todd D
Department of Medicine, University of Hong Kong, Queen Mary Hospital.
Cancer Chemother Pharmacol. 1991;28(1):74-6. doi: 10.1007/BF00684961.
A total of 29 evaluable patients with acute myeloid leukaemia (AML) either in relapse or resistant to initial induction daunorubicin-containing chemotherapy were given a salvage regimen consisting of moderate-dose cytosine arabinoside and mitoxantrone. There were 8 (28%) complete responders (CRs), 4 (14%) partial responders (PRs), and 17 (52%) nonresponders. The duration of CRs was 2+, 2+, 3+, 3, 4+, 4, 5 and 6 months respectively. Two of the eight CR patients were refractory to initial daunorubicin-containing induction therapy and another two had achieved a previous CR lasting less than 6 months. Four of the eight CR patients had received an amsacrine-containing salvage regimen (ATA) prior to administration of the present moderate-dose cytosine arabinoside and mitoxantrone regimen; this indicates the lack of absolute clinical cross-resistance between the present combination and the daunorubicin- or amsacrine-containing regimens. However, the duration of CRs achieved by these patients remains very short and should, if possible, be followed by allogeneic or autologous bone marrow transplantation.
共有29例可评估的急性髓系白血病（AML）患者，这些患者处于复发状态或对含柔红霉素的初始诱导化疗耐药，他们接受了由中剂量阿糖胞苷和米托蒽醌组成的挽救方案。有8例（28%）完全缓解者（CR），4例（14%）部分缓解者（PR），以及17例（52%）无反应者。CR的持续时间分别为2+、2+、3+、3、4+、4、5和6个月。8例CR患者中有2例对含柔红霉素的初始诱导治疗耐药，另外2例曾达到过持续时间不到6个月的CR。8例CR患者中有4例在接受目前的中剂量阿糖胞苷和米托蒽醌方案之前接受过含安吖啶的挽救方案（ATA）；这表明目前的联合方案与含柔红霉素或含安吖啶的方案之间不存在绝对的临床交叉耐药性。然而，这些患者达到的CR持续时间仍然非常短，如果可能的话，后续应进行异基因或自体骨髓移植。
